Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALG-1001 in Symptomatic Focal VMA
NCT02153476Phase 2Completed
- Sponsor
- Allegro Ophthalmics, LLC
- Start
- Feb 2014
- Primary completion
- Jun 2015
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of risuteganib in vitreomacular adhesion (VMA), vitreomacular traction (VMT), sponsored by Allegro Ophthalmics, LLC. Started Feb 2014; status: completed.
02
Drugs
risuteganib
03
Conditions
vitreomacular adhesion (VMA)vitreomacular traction (VMT)
Beyond the preview
Go deeper on NCT02153476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02153476.